Jerome D. Jabbour
2022
In 2022, Jerome D. Jabbour earned a total compensation of $1.7M as Chief Executive Officer at Matinas BioPharma Holdings, a 55% decrease compared to previous year.
Compensation breakdown
| Bonus | $306,500 |
|---|---|
| Option Awards | $792,707 |
| Salary | $575,000 |
| Total | $1,674,207 |
Jabbour received $792.7K in option awards, accounting for 47% of the total pay in 2022.
Jabbour also received $306.5K in bonus and $575K in salary.
Rankings
In 2022, Jerome D. Jabbour's compensation ranked 2,004th out of 5,506 executives tracked by ExecPay. In other words, Jabbour earned more than 63.6% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 2,004 out of 5,506 | 64th |
Division Manufacturing | 1,071 out of 2,985 | 64th |
Major group Chemicals And Allied Products | 458 out of 1,340 | 66th |
Industry group Drugs | 419 out of 1,243 | 66th |
Industry Pharmaceutical Preparations | 303 out of 897 | 66th |
Source: SEC filing on September 19, 2023.
Jabbour's colleagues
We found two more compensation records of executives who worked with Jerome D. Jabbour at Matinas BioPharma Holdings in 2022.
News
Matinas BioPharma Holdings CEO Jerome Jabbour's 2022 pay falls 55% to $1.7M
September 19, 2023
Matinas BioPharma Holdings CEO Jerome Jabbour's 2021 pay jumps 26% to $3.7M
September 22, 2022
Matinas BioPharma Holdings CEO Jerome Jabbour's 2019 pay rises 6% to $1.3M
October 1, 2020
Matinas BioPharma Holdings CEO Jerome Jabbour's 2018 pay slips 1% to $1.3M
September 24, 2019